Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
April 23, 2018
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs…
Read morepress release
April 16, 2018
Geneva, Switzerland and Boston, MA – April 16, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development…
Read morepress release
March 26, 2018
Geneva, Switzerland and Boston, MA – March 26, 2018– ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…
Read moreMay 8, 2019
May 9, 2018
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840